FAST NEWS: Hutchmed swings to profit on strong revenue growth
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced Monday a net profit of $169 million in the first half of 2023, reversing a loss of $163 million in the same period…
FAST NEWS: Hutchmed Sells Cancer Drug’s Overseas Rights for up to $1.13 Billion
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced on Wednesday that it has exclusively licensed Japan’s Takeda Pharmaceutical (TAK.US; 4502.T) to develop, manufacture and sell its metastatic colorectal cancer drug…
FAST NEWS: Hutchmed, Zai Lab, Ascentage Drugs Land on China Reimbursement List
The latest: Products from Hutchmed (China) Ltd. (HCM.US; 0013.HK), Zai Lab Ltd. (ZLAB.US; 9688.HK) and Ascentage Pharma Group (6855.HK) were among 111 new drugs selected for new inclusion in the…
FAST NEWS: Hutchmed Receives Additional Holdings from U.S. Fund
The latest: The Capital Group Companies, Inc., a U.S.-based fund disclosed it purchased 1.285 million shares in Hutchmed (China) Ltd. (HCM.US; 0013.HK) for HK$22.14 million ($2.84 million), raising its stake…
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Cancer drug maker ended a tie-up to bring one of its drugs to North America last week, less than two months after its best-selling product was rejected by the FDA…
FAST NEWS: HutchMed Shares Plunge on U.S. Cancer Drug Rejection
The latest: HutchMed (China) Ltd. (HCM.US; 0013.HK) announced late Monday that its Surufatinib drug for the treatment of advanced neuroendocrine tumors was denied approval by the U.S. Food and Drug…
FAST NEWS: SEC Names Five Chinese Stocks at Threat of Delisting
The latest: The U.S. Securities and Exchange Commission (SEC) announced Thursday that it has placed five Chinese companies on a list of companies that could face the threat of delisting…